AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca has three global R&D centers, in Gaithersburg, MD, South San Francisco, CA and Cambridge’ UK. For more information, please visit www.astrazeneca.com.
Ferring Research Institute, Inc.
Headquartered in San Diego, California, Ferring Research Institute, Inc., (FRI) is a critical component of Ferring Pharmaceutical’s global therapeutics research and discovery engine. Established in 1996, FRI is located in the heart of the Southern California biopharmaceutical community. The center has attracted a diverse group of highly skilled professionals representing over twenty four countries of origin. FRI is focused on the following key therapeutic areas: reproductive health, urology, and gastroenterology. Our state-of-the art facility includes peptide and protein drug design, chemistry, pharmacology, biology, and preclinical ADME capabilities. Historically FRI has focused on the discovery of amino acid-based therapeutics utilizing the body’s signaling hormones. Today FRI is committed to building a portfolio of novel, innovative therapeutics using a wide array of modalities in order to address areas of high unmet medical need in our core therapeutic areas. Driving value through personalized medicine.
Ferring Pharmaceuticals (Ferring) is a private, research-driven specialty biopharmaceutical company active in global markets. The company identifies, develops and markets innovative products in the fields of endocrinology, gastroenterology, infertility, obstetrics, urology and osteoarthritis. In recent years Ferring has expanded beyond its traditional European base: with over 6,500 employees worldwide, it operates subsidiaries in 60 countries and makes its products available in more than 110 countries. The company has emerged as a world leader with one of the largest peptide therapeutics portfolios in the industry. As part of its commitment to developing innovative products to treat diseases with high unmet medical need, Ferring invests heavily in its research infrastructure both in terms of people and technology.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
The PolyPeptide Group
The PolyPeptide Group is a privately-held group of manufacturing sites which focus on proprietary and generic GMP-grade peptides for the pharmaceutical and biotechnological market. With more than 60 years of experience, the Group is committed to the highest quality of peptide manufacturing for commercial peptide drug substances, GMP peptides in clinical trials, or small-scale non-GMP custom syntheses.
The PolyPeptide Group has grown by selective acquisition of existing expertise, culminating in its position today as a leader in peptide manufacturing. The Group has manufacturing facilities in Sweden (Malmo), France (Strasbourg), India (Ambernath) and two sites in the USA (San Diego CA & Torrance CA). As a multinational company with about 520 employees worldwide, its diversity brings breadth and depth of knowledge and experience to the Group.
The Group’s long-established core strength in GMP manufacturing and broad range of services supports peptide & peptide-like projects, including conjugation to non-peptide moieties, from the bench through to commercialization. With continually increasing capacity for GMP manufacturing, the PolyPeptide Group is stronger and better equipped to serve the needs of its customers at all stages of pharmaceutical peptide development. With its multinational organization, strict focus on peptides and solid financial base, the Group offers an almost unique security of supply to its customers.
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company specialized in the discovery, design and development of peptide-based therapeutics. The company has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim and a proprietary pipeline of product candidates, which primarily target specialty diseases with significant unmet needs.
Peptide Therapeutic Foundation
October 20-21, 2022